Biomarkers for cancer-related fatigue and adverse reactions to chemotherapy in lung cancer patients

• Published in: Molecular and clinical oncology Vol. 3; no. 1; pp. 163 - 166
• Main Authors: SHA, FEI, ZHUANG, SHANSHAN, ZHOU, LI, ZHANG, LIQUN, YANG, YUXIAN, ZHANG, SHENGQI, JIANG, YI, QIU, GUODONG, CHEN, CHEN, ZHENG, JIETING, ZHANG, SHUYAO
• Format: Journal Article
• Language: English
• Published: England D.A. Spandidos 01.01.2015; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: 17-hydroxycorticosteroid; adverse reactions to chemotherapy; Analysis; Biological markers; Biomarkers; Cancer patients; Cancer therapies; cancer-related fatigue; Care and treatment; Chemotherapy; Clinical medicine; Cytokines; Diagnosis; Fatigue; Health aspects; interleukin 1; Laboratories; Lung cancer; Oncology; Patients; Prognosis; Psychological aspects; Regression analysis; Risk factors; Studies; Tumor necrosis factor-TNF; tumor necrosis factor-α; Urine; China; lung cancer; 17-hydroxycorticosteroid; adverse reactions to chemotherapy; cancer-related fatigue; interleukin 1; tumor necrosis factor-α
• ISSN: 2049-9450; 2049-9469
• DOI: 10.3892/mco.2014.439

This study was conducted to investigate the biomarkers that appear to be correlated with cancer-related fatigue (CRF) and the adverse reactions (ADRs) to chemotherapy. A total of 100 lung cancer patients were selected and CRF prior to and following chemotherapy was evaluated. The plasma levels of tumor necrosis factor (TNF)-α and interleukin (IL)-1 and the level of 17-hydroxycorticosteroid (17-OHCS) in the urine were analyzed and correlated with CRF and the ADRs associated with chemotherapy. The incidence of CRF was found to be 88.0% and ADRs following chemotherapy occurred in 15.0% of the patients. An increase in the TNF-α and IL-1 levels was detected in patients with CRF. The level of 17-OHCS in the urine was found to be elevated in cases that experienced ADRs following chemotherapy. In conclusion, CRF is closely correlated with increased plasma levels of TNF-α and IL-1. Furthermore, an abnormally elevated 17-OHCS level in the urine may be an important indicator predicting ADR development following chemotherapy.